INBX
Inhibrx Biosciences, Inc.
NASDAQ · Healthcare · Biotechnology · US
$109.35
+4.41%Forward multiples
Based on analyst estimates
- P/E forward
- —
- P/E 2026E
- —
- P/E 2027E
- —
- P/E 2028E
- —
- P/S forward
- 151.31x
Trailing multiples
Trailing twelve months
- P/E TTM
- —
- PEG TTM
- —
- Price / book
- -30.38x
- Price / sales
- —
- Price / cash flow
- -12.20x
Enterprise value
- Enterprise value
- $1.5B
- EV / sales
- —
- EV / EBITDA
- -12.30x
- EV / EBIT
- -11.59x
- Market cap
- $1.6B
Trailing, forward and enterprise-value multiples for the requested listing · Data as of Jun 1, 2026